AI-generated summary
The authors report a randomized, double-blind, sham-controlled pilot trial of home-based intranasal and transcranial photobiomodulation in 43 adults with cognitive symptoms after COVID-19. The overall composite cognitive score difference was not statistically significant, though attention tasks and a younger subgroup improved, and the authors describe the treatment as safe and feasible.
- Participants
- 43
- Who or what was studied
- Adults aged 18 to 65 years with cognitive symptoms at least 12 weeks after COVID-19 infection (post-COVID-19 condition), enrolled in the USA.
- Limits stated in the abstract
- The authors describe this as a small pilot trial with 41 participants analyzed, the composite cognitive result was not statistically significant, the age subgroup finding was exploratory, and larger trials are needed to confirm efficacy.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Sham, Photobiomodulation, Brain fog, Neuroinflammation, Primary outcome, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.